SCHEMBL1163489

SCHEMBL1163489

Nc1ncc(Cc2cc3cccnc3cc2F)nc1N

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.41
CASP6 P55212 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27988286 0.77 MET (0.42) METKDM4EALDH1A1TP53HSP90AA1
SCHEMBL2575351 0.77 MET (0.51) METKDM4EALDH1A1TP53HSP90AA1
SCHEMBL1329537 0.75 CASP6 (0.45) METCASP6KDM4EALDH1A1TP53
SCHEMBL28864698 0.74 NPC1 (0.35) METKDM4EALDH1A1HTTNPC1
SCHEMBL1161458 0.74 ALDH1A1 (0.46) METCASP6KDM4EALDH1A1TP53
SCHEMBL30174396 0.74 ALDH1A1 (0.46) METCASP6KDM4EALDH1A1TP53
Hydrochloric Acid SCHEMBL20563713 0.73 ALDH1A1 (0.46) METCASP6KDM4EALDH1A1TP53
SCHEMBL13676644 0.72 MET (0.46) METCASP6ALDH1A1NPC1
SCHEMBL10162903 0.72 DHFR (0.38) METCASP6KDM4EALDH1A1TP53
Ammonia Solution, Strong SCHEMBL28864710 0.71 MET (0.46) METALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574853-A Heterocyclic oxime compounds NOVARTIS AG 2012-07-11 CN disclosed
WO-2011018454-A1 HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION NOVARTIS AG (CH) 2011-02-17 WO disclosed